Schedule 3 to the Principal Order is amended as follows:

(a) by omitting item 3004 and substituting the following:

3004.	Amorolfine for topical use except –
	(a) when included in Schedule 2 ; or
	(b) in preparations for the treatment of tinea pedis.

(b) by inserting after item 3005 the following:

3006.

Azelastine in topical eye preparations containing 0.05% or less of azelastine.

(c) by inserting after subparagraph (ii) in paragraph (b) of item 3016 the following:

3016M.

Cyclizine in preparations for oral use.

(d) by inserting after subparagraph (ii) in paragraph (b) of item 3041 the following:

3041M.	Ibuprofen in divided preparations, each containing 400mg or less of ibuprofen, in a primary pack containing not more than 50 dosage units when labelled –
	(a) with a recommended daily dose of 1 200mg or less of ibuprofen; and
	(b) not for the treatment of children under 12 years of age –
	except when included in or expressly excluded from Schedule 2 .

(e) by inserting after item 3045 the following:

3045E.

Ketotifen for ophthalmic use in preparations containing 0.025% or less of ketotifen.

(f) by omitting item 3045M and substituting the following:

3045M.

Levonorgestrel for emergency post-coital contraception.

(g) by omitting item 3051 and substituting the following:

3051.

Metoclopramide when combined with paracetamol in divided preparations, packed and labelled only for the treatment of nausea associated with migraine, in packs containing not more than 10 dosage units.

(h) by inserting after item 3059M the following:

3059R.

Oxiconazole in preparations for vaginal use.

(i) by omitting item 3081 and substituting the following:

3081.	Trimeprazine –
	(a) in solid oral preparations except when included in Schedule 2 ; or
	(b) in liquid oral preparations containing 10mg or less of trimeprazine per 5mL.